Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

Microparticles coated with encephalitogenic peptides are effective at treating multiple sclerosis in a mouse model. Aberrant T-cell activation underlies many autoimmune disorders, yet most attempts to induce T-cell tolerance have failed. Building on previous strategies for tolerance induction that e...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology Vol. 30; no. 12; pp. 1217 - 1224
Main Authors: Getts, Daniel R, Martin, Aaron J, McCarthy, Derrick P, Terry, Rachael L, Hunter, Zoe N, Yap, Woon Teck, Getts, Meghann Teague, Pleiss, Michael, Luo, Xunrong, King, Nicholas JC, Shea, Lonnie D, Miller, Stephen D
Format: Journal Article
Language:English
Published: New York Nature Publishing Group US 01-12-2012
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Microparticles coated with encephalitogenic peptides are effective at treating multiple sclerosis in a mouse model. Aberrant T-cell activation underlies many autoimmune disorders, yet most attempts to induce T-cell tolerance have failed. Building on previous strategies for tolerance induction that exploited natural mechanisms for clearing apoptotic debris, we show that antigen-decorated microparticles (500-nm diameter) induce long-term T-cell tolerance in mice with relapsing experimental autoimmune encephalomyelitis. Specifically, intravenous infusion of either polystyrene or biodegradable poly(lactide- co -glycolide) microparticles bearing encephalitogenic peptides prevents the onset and modifies the course of the disease. These beneficial effects require microparticle uptake by marginal zone macrophages expressing the scavenger receptor MARCO and are mediated in part by the activity of regulatory T cells, abortive T-cell activation and T-cell anergy. Together these data highlight the potential for using microparticles to target natural apoptotic clearance pathways to inactivate pathogenic T cells and halt the disease process in autoimmunity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
These authors contributed equally to this work.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.2434